Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02998047
Title A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Actinium Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.